BioNTech’s mRNA therapy for head and neck cancer misses disease control goal; trial continues to track overall survival

Helping the immune system recognize cancer cells is the central idea behind mRNA cancer therapies, but whether they can deliver additional benefits to patients beyond existing treatments still requires testing in clinical trials. BioNTech announced on October 13 that BNT113, when combined with immunotherapy in certain patients with head and neck cancer, did not significantly improve progression-free survival. This is a significant setback, but the trial’s other primary endpoint—overall survival—has yet to be reported.

The Phase 2/3 trial, called AHEAD-MERIT, compares BNT113 plus pembrolizumab (brand name Keytruda) with pembrolizumab alone as first-line treatment. Participants have unresectable recurrent or metastatic head and neck squamous cell carcinoma, and their tumors must be positive for human papillomavirus type 16 (HPV16) and express PD-L1. The results therefore cannot be directly generalized to all patients with head and neck cancer.

BNT113 uses mRNA encoding the HPV16 E6 and E7 proteins to induce an antitumor immune response against these viral antigens. It uses a fixed set of antigens, unlike personalized cancer vaccines tailored to the mutations in each patient’s tumor. Combining it with the immune checkpoint inhibitor pembrolizumab is intended to reduce suppression of the immune response while directing immune recognition. Whether this approach delivers additional efficacy is precisely what the trial is testing.

Progression-free survival measures the time from the trial-defined starting point until disease progression or death; overall survival measures the time until death. This analysis failed to demonstrate a statistically significant advantage for the combination therapy on the former endpoint. RTTNews also noted that, under the trial’s prespecified statistical design, the trial can still achieve a positive outcome if overall survival shows a significant improvement that meets the required criteria, even if the progression-free survival endpoint is not met.

The independent data monitoring committee has recommended continuing the trial as originally planned, and BioNTech remains blinded to the accumulating trial data. The decision to continue follow-up allows the possibility of extending life to be tested, but does not mean that an overall survival benefit has been established. The company’s announcement also did not provide median progression-free survival for the two groups, the hazard ratio, or complete safety results, leaving readers unable to assess the magnitude of the difference or the overall benefit-risk balance from this information.

The market has already reflected disappointment. Reuters reported that BioNTech’s U.S.-listed shares fell nearly 6% at one point in premarket trading after the announcement. The report cited Citi analyst Geoffrey Meacham’s view that disease heterogeneity and a high degree of immune suppression pose challenges to demonstrating additional efficacy. These are interpretations of the difficulties involved in development, rather than confirmed reasons for the trial’s setback.

BNT113 received Fast Track designation from the U.S. Food and Drug Administration in January 2026, but that designation does not constitute approval or guarantee efficacy. Next, the overall survival analysis and more complete efficacy and safety data will determine whether this mRNA therapy targeting viral antigens can offer value supported by clinical evidence beyond existing immunotherapy.